Her2/neu Protein Expression

From Anvita Health Wiki

Contents 1 Pathology 2 Indications 3 Laboratory 4 Methods 5 More General Terms 6 Additional Terms 7 References

Pathology

• overexpression of HER2 (at protein level) in 25% of breast cancer
• overexpression predicts more aggressive disease

Indications

• breast cancer

Laboratory

• ~20% of tests for HER2 protein expression
• LOINC: 18474-7, 31150-6, 32996-1, 42914-2, 48675-3, 48676-1, 49683-6, 51981-9

Methods

• in-situ hybridization

• fluorescent in-situ hybridization ( FISH)

• immunohistochemistry

More General Terms

• molecular diagnostic test

Additional Terms

• receptor tyrosine-protein kinase erbB-2; p185erbB2; C-erbB-2; NEU proto-oncogene; tyrosine kinase-type cell surface receptor HER2; MLN 19; CD340 (ERBB2, HER2, NEU, NGL)

References

1. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 2.2010) 2010 National Comprehensive Cancer Network, Inc.
2. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. PMID: [1]

HER2/Neu (erbB2) protein expression (H2N Oncosite)